Stockreport

Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelof...

Karyopharm Therapeutics Inc.  (KPTI) 
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.karyopharm.com/investor-relations
PDF – Preliminary Total Revenue and U.S. XPOVIO ® (selinexor) Net Product Revenue for the Third Quarter of 2025 Expected to be in the Range of $42 to $44 Million and Approx [Read more]